Analysts Offer Insights on Healthcare Companies: Medpace Holdings (MEDP) and Legend Biotech (LEGN)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Medpace Holdings (MEDP) and Legend Biotech (LEGN).
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Medpace Holdings (MEDP)
Barclays analyst Luke Sergott maintained a Hold rating on Medpace Holdings today and set a price target of $500.00. The company’s shares closed last Tuesday at $520.00.
According to TipRanks.com, Sergott is ranked 0 out of 5 stars with an average return of
Medpace Holdings has an analyst consensus of Moderate Buy, with a price target consensus of $518.25, implying a 3.4% upside from current levels. In a report issued on April 3, TipRanks – xAI also downgraded the stock to Hold with a $526.00 price target.
See the top stocks recommended by analysts >>
Legend Biotech (LEGN)
In a report released today, Etzer Darout from Barclays maintained a Buy rating on Legend Biotech, with a price target of $80.00. The company’s shares closed last Tuesday at $18.69.
According to TipRanks.com, Darout is a 5-star analyst with an average return of
Legend Biotech has an analyst consensus of Strong Buy, with a price target consensus of $54.71, implying a 206.5% upside from current levels. In a report issued on April 7, RBC Capital also maintained a Buy rating on the stock with a $62.00 price target.
Read More on MEDP:
Disclaimer & DisclosureReport an Issue
- New Medpace-Backed PET Tracer Study Targets Precision Cancer Imaging
- Medpace upgraded to Equal Weight from Underweight at Barclays
- MongoDB downgraded, Block upgraded: Wall Street’s top analyst calls
- Medpace initiated with an Outperform at RBC Capital
- Palantir upgraded, Workday downgraded: Wall Street’s top analyst calls
